Du är här


Moberg Pharma: Redeye: Moberg Pharma - Making good progress

The development in the OTC business was solid in 1Q18 and beat our
expectations in almost every aspect. With a positive development in
1Q18 and a stronger USD, we raise our forecasts and our fair value to
SEK 64 (62).

Read more in the Research Update by Klas Palin: https://goo.gl/nEcvL2

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.